Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Jerusalem

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Revue Medicale De Liege|August 11, 2011
[Management and follow-up of a consecutive series of 411 surgically treated breast cancer patients]E Lifrange, C Andre, V Bleret, et al.
Acta Clinica Belgica|May 13, 2009
Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authoritiesI Van Vlaenderen, J L Canon, V Cocquyt, et al.
Anticancer Research|May 4, 2005
Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trialC Focan, M P Graas, M Beauduin, et al.
Breast (Edinburgh, Scotland)|April 2, 2014
European inter-institutional impact study of MammaPrintP G Cusumano, D Generali, E Ciruelos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
Revue Medicale De Liege|August 11, 2011
[Hormone therapy for breast cancer]E Lifrange, C Andre, V Bleret, et al.
Breast Cancer Research and Treatment|December 4, 2017
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapyB Pistilli, T Pluard, A Urruticoechea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2009
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancerG Capri, J Chang, S-C Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyH Bonnefoi, W Jacot, M Saghatchian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Revue Medicale De Liege|August 11, 2011
[Management and follow-up of a consecutive series of 411 surgically treated breast cancer patients]E Lifrange, C Andre, V Bleret, et al.
Acta Clinica Belgica|May 13, 2009
Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authoritiesI Van Vlaenderen, J L Canon, V Cocquyt, et al.
Anticancer Research|May 4, 2005
Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trialC Focan, M P Graas, M Beauduin, et al.
Breast (Edinburgh, Scotland)|April 2, 2014
European inter-institutional impact study of MammaPrintP G Cusumano, D Generali, E Ciruelos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
Revue Medicale De Liege|August 11, 2011
[Hormone therapy for breast cancer]E Lifrange, C Andre, V Bleret, et al.
Breast Cancer Research and Treatment|December 4, 2017
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapyB Pistilli, T Pluard, A Urruticoechea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2009
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancerG Capri, J Chang, S-C Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyH Bonnefoi, W Jacot, M Saghatchian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
Pageof 9